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Accepted 16 December 2013; Published online 5 March 2014AbstractObjectives: Ethical guidelines for human subject research require that the burdens and benefits of participation be equally distributed.
This study aimed to provide empirical data on exclusion of trial participants and reasons for this exclusion. As a secondary objective, we
assessed to what extent exclusion affects generalizability of study results.
Study Design and Setting: Review of trials on secondary prevention of cardiovascular events.
Results: One hundred thirteen trials were identified, of which 112 reported exclusion criteria. One study justified the exclusion criteria
applied. Ambiguous exclusion criteria due to the opinion of the physician (28 of 1125 25%) or physical disability (12 of 1125 11%) were
reported. Within groups of trials that studied similar treatments (ie, beta-blocker, clopidogrel, or statin therapy), baseline characteristics
differed among trials. For example, the proportion of women ranged between 23.1e47.4%, 2.1e38.9%, and 10.6e50.6% for the clopidog-
rel, beta-blocker, and statin trials, respectively. Nevertheless, no evidence was found for heterogeneity of treatment effects.
Conclusion: Almost none of the articles justified the applied exclusion criteria. No evidence was found that inclusion of dissimilar
participants affected generalizability. To allow for a normative discussion on equitable selection of study populations, researchers should
not only report exclusion criteria but also the reasons for using these criteria.  2014 Elsevier Inc. All rights reserved.
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http://dx.doi.org/10.1016/j.jclinepi.2013.12.005human beings for research purposes has to be justified
[1,2]. Inclusion of human participants in medical research
such as randomized clinical trials (RCTs) is ethically diffi-
cult because we ‘‘use’’ humans primarily for the purposes
of science and society [3,4]. Moreover, there have been
serious wrongdoings and highly controversial cases in the
past [5]. Because of the ethical and historical complexity,
many have felt, and still feel, that specific groups should
not be included in clinical trials such as (pregnant) women,
children, and people from low- and middle-income coun-
tries [2,5,6]. However, such exclusion practices have re-
sulted in underrepresentation in research of certain groups
[7]. Therefore, current versions of ethical guidelines require
not only justification of inclusion but also of exclusion
[2,8,9]. For instance, the Council for International Organi-
zations of Medical Sciences guideline for biomedical
research involving human beings requires that ‘‘Groups or
communities to be invited to be subjects of research should
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Key findings
 In our review of cardiovascular trials, virtually all
trials reported the exclusion criteria that were
applied. However, in only 1 out of the 113 trials
that were reviewed, justification of the applied
exclusion criteria was provided.
What this adds to what was known?
 Thus far, most research has focused on ‘‘unneces-
sary’’ use of exclusion criteria without considering
the justifications of applied exclusion criteria. This
study shows that authors do not feel obliged to
report justification for exclusion of study popula-
tions in articles on randomized clinical trials in
cardiovascular diseases. Moreover, we showed
that it was possible to derive generalizable treat-
ment effect estimates in a heterogeneous patient
population.
What is the implication and what should change
now?
 Given the importance of justification of potential
trial populations, we recommend that editors not
only make it mandatory to report on exclusion
criteria used but also require that the authors give
justifications for the applied exclusion criteria.
Explicitly reporting both exclusion criteria and ra-
tionales for these criteria may decrease the use of
ambiguous exclusion criteria, or at the very least,
readers can more easily judge whether exclusion
of groups of patients was justified.
be selected in such a way that the burdens and benefits of
the research will be equitably distributed. The exclusion
of groups or communities that might benefit from study
participation must be justified’’ [2]. Likewise, the Canadian
Tri-Council Policy Statement 2 [9] stresses that ‘‘taking
into account the scope and objectives of their research,
researchers should be inclusive in selecting participants.
Researchers shall not exclude individuals [.] unless there
is a valid reason for the exclusion.’’
Although ethical concerns of inappropriate exclusion
of trial populations are expressed in guidelines [9], it is
currently unknown to what extent benefits and burdens of
research are equally distributed. It is not straightforward
to evaluate the current selection of study location and pop-
ulation because trial databases do not require reporting
which potential study populations have been excluded
and why. In addition, considerations on equitable distribu-
tion of burdens and benefits may be part of the evaluation
of study protocols in research ethics committees, but thenotes of these meetings are usually not publicly available.
Therefore, a logical first step to assess in what proportion
of studies unbalanced selection of patient groups was
applied is literature reviews on reporting exclusion criteria
and the grounds for using these criteria. Information on
exclusion criteria is likely to be available in articles because
both the CONsolidated Standards of Reporting Trials
(CONSORT) and the Standard Protocol Items: Recommen-
dations for Interventional Trials (SPIRIT) statements
require the reporting of exclusion criteria [10,11]. Although
these data not necessarily reveal whether study populations
have been deliberately excluded, they may nevertheless
show whether and to what extent the reasons for exclusion
of trial participants have been transparent on a more general
level and hence whether there are concerns of unjustifiable
exclusion of study populations. This article is the first to
study the use of exclusion criteria in this way. There have
been previous studies on the use of exclusion criteria, but
they have focused on their unnecessary use [12e14]. Thus
far, no study explored whether researchers themselves justi-
fied the exclusion criteria that were applied. In this article,
we will report both the current status of the application of
exclusion criteria and the justification of exclusion criteria
using reported data from RCTs on secondary prevention of
cardiovascular events. We have chosen studies on this topic
because we expected a large number of trials from a large
number of research groups, thus increasing representative-
ness of the sample.
Apart from ethical reasons for justifying exclusion, there
are also methodological reasons: if certain patient popula-
tions are not represented in RCTs, this may reduce general-
izability of trial results. The previous studies that explored
the application of exclusion criteria assumed that any
exclusion of potential subjects hampers generalizability
[12e14]. However, studies comparing RCTs and non-
randomized studies (typically with less stringent inclusion
and exclusion criteria) found little differences in the treat-
ment effects [15e18]. Therefore, as a secondary objective
of our study, we assessed to what extent inclusion of
different patient groups affects generalizability and thus re-
sults in different treatment effects.2. Methods
2.1. Review of trials on secondary prevention of
cardiovascular events
We conducted a review to assess the current practice in
reporting and justification of exclusion criteria in RCTs. We
focused on the rationale for excluding groups of subjects by
extracting information on included subjects and reported
exclusion criteria. Using the query described in Appendix
at www.jclinepi.com, we searched MEDLINE (using
PubMed) for articles indexed from October 1, 2010, till
May 31, 2012. Based on the title and abstract, we identified
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which were defined as trials including patients with a
stroke, myocardial infarction (MI), heart failure, cardiac
arrhythmia, peripheral vascular disease, or patients under-
going coronary artery bypass grafting (CABG) or percuta-
neous coronary intervention. In addition, participants had to
be randomized to one of the following treatments: statins,
platelet aggregation inhibitors, beta blockers, angiotensin-
converting enzyme inhibitors, or angiotensin II receptor
blockers and a placebo or active comparator. Furthermore,
the articles needed to be written in English and describe a
single trial. To allow for a fair comparison between
different article types (eg, main analyses of trial results
vs. post hoc analyses), we also searched for design articles
and primary publications using crossreferences and trial
registries. Information from different sources related to a
single trial was combined into a single entry.2.2. Data extraction
Of the included articles, data were extracted on applied
exclusion criteria, the justification of exclusion criteria,
baseline characteristics, and treatment effect estimates.
The number of exclusion criteria reported by a single article
is often large; to limit this number, data were extracted on
18 a priori defined criteria with the option to include more
if relevant. In the case of inclusion criteria, we defined the
opposite as an exclusion criterion. For example, if for a
particular trial, age of 65 years and older was reported as
an inclusion criterion, age below 65 years was considered
as an exclusion criterion. Finally, we determined whether
a rationale for exclusion criteria was provided. This was
defined as any point-by-point explanation about why exclu-
sion criteria were applied. This allowed us to differentiate
between articles that mentioned very explicit criteria such
as any contraindication or high risk for loss to follow-up,
but otherwise offered no explanation, from studies that
did offer justification. Exclusion criteria were divided into
those needing justification and those that were self-
explanatory. Criteria were judged to be self-explanatory
when there was one obvious explanation for excluding
these patients. For example, a self-explanatory exclusion
criterion would be a contraindication to the medication un-
der study (eg, allergy). The rationale behind excluding such
patients is obviously safety concerns, and patients with con-
traindications would not be considered future users.
Obviously, RCTs exploring different treatments are also
likely to differ regarding exclusion criteria and groups of
participants included. Therefore, to allow for a fair compari-
son, we selected (from the larger overall review) three
groups of trials that explored the effect of clopidogrel
(n 5 20), beta-blocker (n 5 6), or statin therapy (n 5 13).
These (phase III) trials compared treatment (clopidogrel,
beta-blocker, or statin therapy) to an active control or placebo,
on (composite) outcomes including death,MI, or stroke. Most
studies randomized participants to add-on treatment, forexample, adding clopidogrel to aspirin treatment and
comparing this with aspirin plus placebo or usual care.2.3. Data analysis
All analyses were performed using R forWindows, version
3.0.2 (R Foundation for Statistical Computing,Vienna,
Austria) [19]. The flowchart of the MEDLINE search was
created using the Diagram Designer program [20]. Baseline
characteristics and effect estimates were pooled and weighted
by the number of subjects. To assess generalizability of treat-
ment effect estimates, we compared baseline characteristics
of study participants across trials and determined the heteroge-
neity of treatment effects.We chose not to (statistically) test for
thepresence of treatment heterogeneity. Instead, treatment het-
erogeneity was quantified using the I2 statistic [21] and its pre-
cision by a 95% confidence interval (95% CI). The I2 statistic
represents the percentage of variation in effect estimates across
studies explained by actual differences (ie, not due to chance).
An I2 value of 0e25%, 25e50%, 50e75%, andO75% can be
interpreted as no, low,moderate, or high heterogeneity, respec-
tively [22].Additionally,we explored if therewere any signs of
treatment effect modification by age and proportion of women
(ie, if there was a trend of increasing or decreasing treatment
effect dependent on age or gender) [23]. These baseline char-
acteristics were chosen because we expected them to be uni-
formly reported. Although we did not expect a large number
of trials to exclude subjects based on age or gender, we do
expect that exclusion due to other reasons will impact the
gender and age distribution. For example, if the number of co-
morbidities increases with age, excluding subjects based on
any comorbidity will decrease the average age in the study
sample. Therefore, mean age and gender are used as proxies
for differences in the application of exclusion criteria. Finally,
to evaluate the possibility that treatment heterogeneity was
dependent on exclusion criteria and not (or not only) on base-
line characteristics, we evaluated whether treatment effects
changed when stratifying for three exclusion criteria. These
criteria (exclusion due to any medication usage at baseline,
nonna€ıve for intervention, and opinion of physician) were
selected (post-hoc) because they were applied around 50%
of the times, thus ensuring approximately equally sized strata.3. Results
3.1. Description of included trials
The MEDLINE search resulted in 3,001 potentially rele-
vant articles, of which 113 were included (see Fig. 1 for the
flow and Appendix at www.jclinepi.com for references of
the 113 included articles). Among the 113 included RCTs,
17 articles (15%) reported only on the design of the study.
Characteristics of trial participants were reported in 96
(85%) of the articles, which included a median of 447 sub-
jects [interquartile range (IQR): 192e2,141].
Fig. 1. Flow of identified publications in the review of RCTs in second-
ary prevention of cardiovascular events. RCT, randomized clinical
trial.
Table 1. Reported exclusion criteria (with percentage and 95% confidenc
(published October 2010eMay 2012)a
Criterion
All RCTs (N[ 112)b
RCT o
the
N (%) 95% CI N (%
Self-explanatory criteria
Contraindication to intervention 73 (65) 56, 74 3 (50
Any impaired renal condition 63 (56) 47, 65 4 (67
Any impaired liver condition 59 (53) 43, 62 5 (83
High risk of bleeding 56 (50) 41, 59 0
Criteria requiring justification
Age below 18 yr 78 (70) 61, 78 4 (67
Other age restrictions 41 (37) 28, 46 3 (50
Pregnant and/or fertile 53 (47) 38, 57 0
Lactating women 30 (27) 19, 35 0
Female gender 1 (1) 0, 3 0
Male gender 0 d 0
Any medication usage at baseline 80 (71) 63, 80 4 (67
Nonna€ıve for Intervention 40 (36) 27, 45 3 (50
Opinion of physician 28 (25) 17, 33 3 (50
Indication for either treatment arm 13 (12) 6, 18 0
Likely to be lost to follow-up 9 (8) 3, 13 0
Short life expectancy 45 (40) 31, 49 2 (33
Lack of cognition or mental impairment 16 (14) 8, 21 2 (33
Physical disability 12 (11) 5, 16 0
Abbreviations: RCT, randomized clinical trial; CI, confidence interval.
a 95% Confidence intervals are based on the asymptotic Wald approxim
b One study did not report any exclusion criteria.
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Exclusion criteria were reported in 112 articles (99%), a
median of six exclusion criteria were reported per article
(IQR: 4e6; range: 0e12). The prevalence of different exclu-
sion criteria is presented in Table 1 and stratified for criteria
needing justification and those criteria that are self-
explanatory. Self-explanatory exclusion criteria included
exclusion due to high bleeding risk (56 of 112 5 50%),
contraindications for the studied intervention (73 of
112 5 65%), and impaired renal (63 of 112 5 56%) or liver
(59 of 112 5 53%) function. Exclusion criteria that poten-
tially require justification are exclusion of pregnant or fertile
women [reported by 53 (47%) of the trials] and exclusion of
lactating women [30 (27%), all of which also excluded the
category pregnant or fertile women]. Studies not excluding
lactating or fertile/pregnant women reported a relatively high
median age (64 years; IQR 62e67, for the first group and
64 years; IQR 62e67 for the latter group), indicating that on-
ly a small number of women would be affected by excluding
lactating or fertile/pregnant women. Other criteria needing
justification are exclusion due to impaired cognition (16 of
112 5 14%), physical disability (12 of 112 5 11%), medi-
cation use at baseline (80 of 112 5 71%), nonnaivety to the
studied intervention (40 of 112 5 36%), specific indication
for either treatment arm (13 of 112 5 12%), short life
expectancy (45 of 112 5 40%), based on the opinion of
the physician (28 of 112 5 25%), or exclusion due to ane interval) in RCTs in secondary prevention of cardiovascular events
f beta-blocker
rapy (N [ 6)
RCTs of clopidogrel
therapy (N [ 20)
RCTs of statin therapy
(N [ 13)
) 95% CI N (%) 95% CI N (%) 95% CI
) 10, 90 15 (75) 56, 94 6 (46) 27, 81
) 29, 100 6 (30) 10, 50 11 (85) 65, 100
) 54, 100 4 (20) 2, 38 12 (92) 78, 100
d 13 (65) 44, 86 1 (8) 0, 22
) 29, 100 13 (65) 44, 86 9 (69) 44, 94
) 10, 90 6 (30) 10, 50 6 (46) 19, 73
d 7 (35) 14, 56 6 (46) 19, 73
d 4 (20) 2, 38 4 (31) 6, 56
d 0 d 0 d
d 0 d 0 d
) 29, 100 17 (85) 69, 100 7 (54) 27, 81
) 10, 90 9 (45) 23, 67 9 (69) 44, 94
) 10, 90 5 (25) 6, 44 3 (23) 0, 46
d 0 d 1 (8) 0, 22
d 3 (15) 0, 31 0 d
) 0, 71 7 (35) 14, 56 3 (23) 0, 46
) 0, 71 0 d 1 (8) 0, 22
d 0 d 1 (8) 0, 22
ation [27]; values below 0 and 100 were truncated.
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Furthermore, children (ie, participants aged!18 years) were
excluded in 78 trials (70%), and exclusion based on age,
other than age !18 years, was reported in 41 trials (36%),
often resulting in the inclusion of older subjects. A single
trial (1%) mentioned excluding women. In a sensitivity anal-
ysis, we explored whether exclusion criteria differed be-
tween publications from journals with a high (O5) and
low (5) impact factor (Appendix at www.jclinepi.com).
This revealed that trials published in journals with a higher
impact factor tended to apply more exclusion criteria.
Because differences in exclusion criteria in such a large
group of trials might occur because of differences in, for
example, treatment or outcome under study, we also explored
the exclusion criteriamentioned in a subset of trials, that is, tri-
als on clopidogrel (n5 20), beta-blocker (n5 6), or statin ther-
apy (n 5 13). These trials were similar in the studied
treatments and the outcomes (see Appendix at www.jclinepi.
com for details). Given this similarity, one might also except
that within each group of trials, similar exclusion criteria were
applied. This was indeed the case for some criteria, forTable 2. Baseline characteristics of study participants in RCTs on beta
cardiovascular events (published October 2010eMay 2012)
Baseline characteristic
Beta-blocker RCTs Clopidogrel RCT
Range
(minemax)
No. of
studies
(N [ 6)
Range
(minemax)
s
(N
Number of subjects 70e2,708 6 60e13,608
Women (%) 2.1e38.9 6 23.1e47.4
Mean age (yr) 46.6e75.7 6 59.0e68.6
Mean weight (kg) 84.1 1 87.8
Mean height (cm) 172.7 1 d
Mean BMI (kg/m2) 25.7e28.0 4 24.2e30.0
Currently
smoking (%)
4.2e17.5 3 12.8e49.8
Previously smoking 73 1 d
Never smoked d 0 d
White race (%) 70 1 88.8e93.7
Black race (%) 24 1 1
Asian race (%) d 0 7
Hispanic race (%) 6 1 d
Diabetes (%) 20.6e35.5 4 19.4e45.1
Hypercholesterolemia
(%)
43.0e63.0 4 15.7e82.6
Hypertension (%) 59.0e82.9 4 40.1e88.8
Mean serum
cholesterol
(mmol/L)
4.8 1 4.0
Mean systolic
BP (mm Hg)
113.6e140.9 6 129.4e130.0
Mean diastolic
BP (mm Hg)
71.0e90.8 4 77.9e80.0
Mean heart rate 73.0e81.5 6 75.0
History of MI (%) 40.0e50.3 3 3.8e53.6
History of ST (%) 10 1 2.0e7.7
Abbreviations: RCT, randomized clinical trial; min, minimum; max, ma
infarction; ST, stroke.
Displayed information is based on articles that allowed for extraction of p
or mean percentage if there were two or more RCTs included. If only one RC
RCT is presented.example, 12 of the 13 statin trials excluded subjects with liver
impairment at baseline. Contrary to this, some exclusion
criteria were more variably applied, within groups of trials.
For example, within the group of clopidogrel trials, nineRCTs
(45%) excluded nonnaive subjects, whereas 11 (55%)
included such participants. In the group of statin trials, six tri-
als (46%) excluded pregnant or fertile women. Similarly
within the beta-blocker RCTs, three of six (50%) focused on
a specific age group of adults.
Only one article reported a rationale for the applied
exclusion criteria. This particular study assessed the effect
of clopidogrel in patients undergoing CABG and used a
nonfatal end point [24,25]. The authors explain that sub-
jects with a current malignancy were excluded by stating:
‘‘Higher risk of early postoperative mortality’’ [25].3.3. Generalizability
The baseline characteristics of included trials showed a
large range in patient characteristics between trials
(Table 2), also when focusing on the subsets of trials on-blocker, clopidogrel, or statin therapy in secondary prevention of
s Statin RCTs All RCTs
No. of
tudies
[ 17)
Range
(minemax)
No. of
studies
(N [ 12)
Range
(minemax)
No. of
studies
(N [ 96)
17 44e9,251 12 36e26,449 96
17 10.6e50.6 12 2.1e78.4 96
16 58.4e71.0 12 46.6e81.0 88
1 78.4e85.7 2 75.2e92.8 15
0 170.7e172.5 2 167.8e172.7 7
10 23.0e28.8 4 23.0e31.9 46
15 12.9e58.7 9 4.2e59.8 73
0 37.1e63.5 2 23.7e72.5 13
0 24 1 23.5e48.5 7
3 90.9e94.3 2 69.9e98.8 21
1 d 0 0.9e100 10
1 d 0 5.0e100 8
0 d 0 3.0e10.3 3
16 14.7e44.0 10 1.5e100 85
16 28.5e40.7 2 10.8e87.9 56
15 43.0e82.7 10 29.9e90.4 75
1 4.5e6.2 4 3.8e6.2 11
2 127.0e138.9 4 96.9e145.3 38
2 71.1e81.8 4 60.5e90.8 30
1 67.0e68.0 2 64.2e91.1 26
12 18.5e81.0 6 1.5e81.0 57
6 4.9e9.4 2 2.0e99.8 30
ximum; BMI, body mass index; BP, blood pressure; MI, myocardial
atient characteristics. The range gives minimum and maximum mean
T reported on the respective characteristics, the point estimate of this
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proportion of women included ranged from 23.1% to 47.4%
for the clopidogrel, 2.1e38.9% for the beta-blocker, and
10.6e50.6% for the statin RCTs. Other examples could be
differences in the proportion of subjects with, for example,
diabetes, hypertension, and hypercholesterolemia (Table 2).
Note that although one trial reported to exclude women,
the minimum included proportion of women was 2.1%.
Among the clopidogrel trials, 13 studies (80%) allowed
for extraction of the treatment effect. Of the seven trials not
reporting outcome data, three were design articles, and in
three trials, no outcomes were observed (eg, due to the
outcome being of secondary importance). The reported risk
ratio (RR) for clopidogrel vs. active or placebo add-on ther-
apies ranged between 0.13 and 0.99 (pooled RR 5 0.77;
95% CI: 0.67, 0.88), for the composite end point of mortal-
ity, MI, stroke, revascularization, and stent thrombosis (see
Appendix at www.jclinepi.com). Plotting the RR against
the proportion of women or mean age of the included sub-
jects did not show any dependency (Fig. 2). This is in lineFig. 2. Forest plot of the effect of clopidogrel on the composite end point o
thrombosis, ordered by the proportion of women or mean age of the individua
indicate 95% confidence intervals of the risk ratios. N reflects the sample s
mean age and was excluded. SD, standard deviation.with the I2 statistic, which indicated little heterogeneity
(I2 5 16%; 95% CI: 0, 35).
For the group of statin trials, treatment effects could be
extracted from 12 articles (92%). The RR for the composite
end point of mortality, MI, stroke, and revascularization
ranged between 0.25 and 1.50 (pooled RR 5 0.82; 95%
CI: 0.75, 0.91). Graphics did not suggest any dependency
between gender or age and the treatment effect (Fig. 3)
and neither did the I2 statistic (I2 5 12%; 95% CI: 0, 31).
Among the beta-blocker trials, using data from 5 studies
(83%), the RR for the mortality and/or MI end point ranged
between 0.68 and 2.25 (pooled RR 5 0.91; 95% CI: 0.68,
1.21). After excluding the most extreme observation of
2.25, the range was an RR of 0.68e0.94. As with the two
previous examples, the graphical display (Fig. 4) and the
I2 statistic did not suggest any heterogeneity (I2 5 0%,
95% CI: 0, 100). However, because of small sample size,
the 95% CI was large, indicating a lack of precision.
Finally, we explored whether treatment effects were
dependent on the following exclusion criteria: ‘‘anyf mortality, myocardial infarction, stroke, revascularization, and stent
l trials. Triangles indicate treatment effects (risk ratio). Horizontal bars
ize including both genders. One of the clopidogrel trials did not report
Fig. 3. Forest plot of the effect of statins on the composite end point of mortality, myocardial infarction, and revascularization, ordered by the pro-
portion of women or mean age of the individual trials. Triangles indicate treatment effects (risk ratio). Horizontal bars indicate 95% confidence
intervals of the risk ratios. N reflects the sample size including both genders. SD, standard deviation.
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‘‘opinion of physician’’; see Appendix at www.jclinepi.
com. No dependency between the treatment effect esti-
mates and exclusion criteria was observed.4. Discussion
Key findings of this study are that (1) a rationale for
exclusion criteria is hardly ever reported and (2) the applied
exclusion criteria differed considerably between studies
exploring the same treatment, yet despite differences in
baseline characteristics between these studies, there was
no evidence for impaired generalizability. In the following,
we will discuss these findings.
Although almost all RCTs in our review of secondary pre-
vention of cardiovascular events reported exclusion criteria
(112 of 113 5 99%), only one article provided reasons for
the criteria that had been applied. Therefore, it is difficult
to assess whether the inclusion and exclusion of trial partic-
ipants in these trials was justified. We categorized exclusion
criteria into those needing justification and those that are
self-explanatory. Obviously, this is to some extent anarbitrary decision, and other categorizations are also
possible. However, we expect that most would agree that
justification is not needed for excluding patients due to
safety reasons such as contraindications for the intervention
under study. We deemed other criteria less self-explanatory,
and these would require justification. For example, in some
occasions, participants were excluded because of a ‘‘short
life expectancy’’ (45 of 112 5 40%). Exclusion for this
reason possibly has to do with statistical power when study-
ing nonmortality outcomes. This can, however, also be inter-
preted as gatekeeping [26], meaning that some groups of
subjects may have been eligible to participate but have none-
theless been excluded. Another example is ‘‘opinion of the
physician’’ (28 of 1125 25%). This criterionmay imply that
researchers in their roles as physicians have made individu-
alized judgments for patients, which should typically be
avoided in a research context. Other exclusion criteria, for
example, those relating to age or pregnancy, might be seen
as self-explanatory by some. However, we still viewed these
as needing justification because there can be multiple
nonexclusive reason for applying these criteria. For
example, children could be excluded because treatment
effectiveness was expected to differ but also because of the
Fig. 4. Forest plot of the effect of beta blockers on the composite end point of mortality and myocardial infarction, ordered by the proportion of
women or mean age of the individual trials. Triangles indicate treatment effects (risk ratio). Horizontal bars indicate 95% confidence intervals
of the risk ratios. N reflects the sample size including both genders. SD, standard deviation.
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excluding pregnant/fertile or lactating women could be
due to expected adverse event or other reasons such as the
need for closer monitoring, which might be infeasible during
the trial. In our sample of trials, almost half of the articles
excluded pregnant/fertile women and one-fourth excluded
lactating women. However, because of the relatively older
target population of studies of secondary prevention of car-
diovascular events, it remains uncertain whether indeed
women have been excluded inappropriately, and if so, how
many have been unfairly excluded. In Section 1, we have
already mentioned that these reasons for exclusion of poten-
tial trial participants are probably not published elsewhere.
Hence, there is a potential risk of unjustifiable exclusion.
In three groups of RCTs of the same treatment, there
was no uniform application of exclusion criteria, and base-
line characteristics differed considerably between studies.
Despite this, the observed treatment effects were similar
across trials. This suggests that findings from these trials
can be generalized across groups of participants; that is, in-
clusion of different groups of participants did not seem to
impair generalizability of treatment effects. Generaliz-
ability was assessed using the I2 statistics and by graphi-
cally determining whether there was a trend betweentreatment effect estimates and the baseline characteristics,
age and gender; no trend was found. However, it could be
possible that researchers did not a priori expect difference
in treatment effects between age or gender subgroups, thus
allowing for differences in exclusion rates for the different
subgroups. On the other hand, it seems likely that age and
gender are related to other patient characteristics such as
frailty and polypharmacy. Thus, age and gender might still
be used as proxies for treatment effect modification be-
tween treatment and other baseline characteristics. We
focused, however, on age and gender because these patient
characteristics were reported by almost all trials.
Despite careful considerations, this review potentially
suffers from a few weaknesses. Our review focused on trials
on secondary prevention of cardiovascular events. Our find-
ings may therefore be only applicable to this particular clin-
ical domain and not to other domains. In addition, we
conducted our search using the MEDLINE database only.
Hence, RCTs not indexed by MEDLINE were not included
in our review. Most, if not all, journals with a high impact
factor are indexed by MEDLINE. However, this is not the
case for lower impact journals. Inclusion of more lower
impact publications, from other databases, could possibly
change our findings. As a sensitivity analysis, we therefore
643A.F. Schmidt et al. / Journal of Clinical Epidemiology 67 (2014) 635e644stratified exclusion criteria by the impact factor (O5 vs.
5), which suggested that lower impact publications
reported less exclusion criteria. Thus, the percentage of re-
ported exclusion criteria is possibly somewhat inflated by
only using MEDLINE (PubMed). However, it seems un-
likely that searching additional databases would markedly
increase the percentage of articles justifying exclusion
criteria. Similarly, we recognize that our MEDLINE search,
of which 4% of the hits were included, might have been
overly sensitive. Although inefficient, this might neverthe-
less reduce the likelihood of excluding relevant publica-
tions. In the present review, we observed differences
between baseline characteristics of trial populations. It
seems likely that these differences are not only explained
by different application of exclusion criteria but also
(partially) reflect differences in available patient popula-
tion. Regardless of the causes of these differences in base-
line characteristics, we did not find any indication of
treatment heterogeneity depending on these differences.
Heterogeneity was assessed using I2 and by determining
whether there was a trend in the treatment effect estimates
per study and the mean age and the proportion of women.
Because of the relative small number of studies, precision
of these methods was sometimes lacking. This was most
pronounced in the beta-blocker example, in which the
95% CI of the I2 included 0% and 100%. In the clopidogrel
and statin examples, the precision was higher, indicating an
upper level of 35% heterogeneity. Given these limitations,
we cannot conclude that there is in fact no treatment hetero-
geneity but merely that we could not detect any. Another
issue is that the pooling of baseline characteristics, treat-
ment effect estimates, and the exploration of heterogeneity
are based on meta-analysis methods. Given that our interest
is not on estimating any clinically relevant treatment effect
estimates, no assessment of risk of bias of the individual
studies was performed. On the other hand, little heterogene-
ity was found between the three trial subgroups, indicating
that if a bias assessment had been applied, results would not
differ markedly.
Although ethical guidelines require justification of
exclusion, this study shows that authors do not feel obliged
to provide this rationale. However, if potential subjects are
excluded because of expected differences in treatment
effectiveness (or harm), it seems very relevant to report this
information. It might be beneficial when reporting guide-
lines such as the CONSORT or the SPIRIT statement would
recommend such reporting. In fact, the recent SPIRIT state-
ment on RCT protocols [11] advises researchers to do just
this and states: ‘‘Certain eligibility criteria warrant explicit
justification in the protocol, particularly when they limit the
trial sample to a narrow subset of the population’’ [11]. In
line with the SPIRIT statement, we believe that the quality
of RCT reporting would improve when researchers report
justification of exclusion criteria. Whether this is done in
the RCT protocol, the primary publication, trial registries,or in any other publicly available documentation is of sec-
ondary importance.5. Conclusion
Although ethical guidelines require justification of
exclusion of study populations [8,10], this study shows that
authors do not feel obliged to provide this rationale in their
articles. In line with these guidelines, we emphasize that re-
searchers should not only report exclusion criteria but also
discuss why these exclusion criteria were used and to what
extent exclusion of those subjects could affect generaliz-
ability of treatment effects. Explicitly reporting both exclu-
sion criteria and rationales for these criteria may decrease
the use of ambiguous exclusion criteria, or at the very least,
readers can more easily judge whether exclusion of groups
of patients was justified.Acknowledgments
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